rs891512 — NOS3

Intronic NOS3 variant that alters splicing factor binding and is associated with blood pressure and cardiovascular risk, with effects that are amplified by physical activity

See your personal result for NOS3

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

NOS3 IVS25+15 — The Blood Pressure Variant Wired to Exercise

Your NOS3 gene encodes endothelial nitric oxide synthase (eNOS), the enzyme that produces nitric oxide (NO)11 nitric oxide (NO)
a gaseous signaling molecule that dilates blood vessels, prevents platelet aggregation, and protects the endothelium from inflammation and atherosclerosis. Without adequate NO, blood vessels stay more constricted and arterial stiffness rises in the cells lining your blood vessels. Among the many variants studied in this gene, rs891512 stands out for a specific reason: in a study genotyping 11 NOS3 polymorphisms across 726 participants from the MRC Ely Study, it was the only variant significantly associated with blood pressure22 only variant significantly associated with blood pressure
Vimaleswaran KS et al. Habitual energy expenditure modifies the association between NOS3 gene polymorphisms and blood pressure. Am J Hypertension, 2008 at rest. The association was strongest in physically active individuals, making rs891512 a clinically relevant gene-lifestyle interaction variant.

The Mechanism

rs891512 is located within intron 25 of NOS3 (IVS25+15 G>A) — 15 nucleotides into the intron after exon 25. On the GRCh38 reference genome the G allele is most common (~80% globally), while the A allele appears at roughly 20% in Europeans. Although intronic variants do not change the amino acid sequence, they can alter splicing factor binding33 splicing factor binding
Splicing factors are proteins that direct how pre-mRNA introns are removed and exons joined together. Binding sites for these factors are concentrated near intron-exon junctions, and a variant that alters a binding site can cause aberrant splicing — including exon skipping or inclusion of intronic sequence — that disrupts the final protein. Bioinformatic analysis of rs891512 predicts that the A allele alters binding of the SF2/ASF splicing factor44 SF2/ASF splicing factor
Serine/arginine-rich splicing factor 1 (SRSF1), a key regulator of constitutive and alternative splicing that binds exonic and intronic splicing enhancers, potentially causing defective splicing that yields a truncated or altered eNOS protein with lower enzymatic activity.

This mechanism aligns with what is known about NOS3 alternative splicing: truncated eNOS isoforms can form heterodimers with full-length enzyme and reduce overall NO output55 NO output
Lorenz M et al. Alternative splicing in intron 13 of the human eNOS gene: a potential mechanism for regulating eNOS activity. FASEB J, 2007. The functional consequence is lower vascular NO bioavailability — the same downstream effect as the well-characterized Glu298Asp (rs1799983) coding variant, but through a different molecular route.

The Evidence

The most rigorous study of rs891512 comes from the MRC Ely Study of 726 adults66 MRC Ely Study of 726 adults
Vimaleswaran KS et al. Habitual energy expenditure modifies the association between NOS3 gene polymorphisms and blood pressure. Am J Hypertension, 2008. Researchers genotyped 11 NOS3 polymorphisms and found that among all variants tested, only IVS25+15 (rs891512) was independently associated with resting blood pressure. GG homozygotes had diastolic BP 2.8 mmHg lower (P = 0.016) and systolic BP 1.9 mmHg lower (P = 0.018) than A-allele carriers. Crucially, this effect was amplified by physical activity: in the most active tertile, GG homozygotes showed BP reductions of 4.9 mmHg diastolic and 3.8 mmHg systolic compared to A-allele carriers — a compelling gene-lifestyle interaction.

Cardiovascular disease associations have been reported in a Tunisian cohort of 274 CAD cases and 162 controls77 a Tunisian cohort of 274 CAD cases and 162 controls
Letaief Afef et al. Endothelial nitric oxide gene polymorphisms and their association with coronary artery disease in Tunisian population. Anatol J Cardiol, 2017. The A allele was significantly enriched in cases (28.8%) versus controls (16.9%), with an OR for CAD of 1.99 (95% CI 1.40–2.82; P < 0.001). The genotype distribution difference between cases (AA 11.4%, GA 34.7%, GG 53.9%) and controls (AA 2.5%, GA 29.7%, GG 67.8%) was also statistically significant (P = 0.006). A smaller Chilean study in type 2 diabetes patients88 smaller Chilean study in type 2 diabetes patients
Seelenfreund D et al. Association of the intronic polymorphism rs891512 (G24943A) of the endothelial nitric oxide synthase gene with hypertension in Chilean type 2 diabetes patients. Diabetes Res Clin Pract, 2012 (n = 93 patients, 76 controls) found significant association of the A allele with hypertension (p < 0.05), with A-allele frequency of 15% in that population.

In exercise genetics, deep-targeted NOS3 sequencing found that after vigorous-intensity cycling (100% VO2 peak), the A allele explained 5.6–7.6% of the variance in post-exercise hypotension among African American participants (P < 0.001 for diastolic BP), with minor allele carriers showing a substantially larger post-exercise BP decrease than GG homozygotes. The effect was absent at moderate intensity (60% VO2 peak), indicating the interaction is exercise-intensity-specific.

Practical Implications

The core finding for A-allele carriers is that your resting blood pressure tends to run modestly higher than the GG genotype. The good news embedded in the data is that the genetic disadvantage shrinks substantially with physical activity — GG carriers who are active show the largest benefit, but the data also imply that A-allele carriers who are habitually active narrow the BP gap considerably. Vigorous aerobic exercise appears to be particularly important, as the gene-exercise interaction is strongest at high exercise intensity.

Dietary nitrate from beetroot and nitrate-rich vegetables offers an alternative NO production pathway that is independent of eNOS altogether — it proceeds via the entero-salivary nitrate-nitrite-NO pathway. For A-allele carriers with elevated BP or blunted eNOS function, regular consumption of high-nitrate vegetables or beetroot juice (400–500 mg nitrate) can measurably reduce blood pressure and improve endothelial function.

Interactions

rs891512 is located in the same gene as the well-characterized Glu298Asp variant (rs1799983)99 Glu298Asp variant (rs1799983)
missense variant changing amino acid 298 from glutamic acid to aspartic acid, making eNOS more susceptible to proteolytic degradation and reducing NO output, which affects eNOS protein stability. The two variants are in incomplete linkage disequilibrium, meaning they provide partially additive information about NOS3 function. Carrying risk alleles at both positions could compound reduced NO production through distinct mechanisms — impaired splicing (rs891512) and accelerated protein degradation (rs1799983).

The rs891512 exercise-BP interaction also suggests synergy with the promoter variant rs2070744 (T-786C)1010 rs2070744 (T-786C)
a regulatory variant that reduces NOS3 gene expression by approximately 25%; the T allele is protective and the C allele reduces promoter activity and eNOS mRNA levels, which affects eNOS transcription level. Compound actions for NOS3 multi-variant combinations should be considered when a user carries risk alleles at rs891512 and rs1799983 or rs2070744 simultaneously.

Nutrient Interactions

dietary nitrate increased_need
L-arginine altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant.

GG Normal Splicing Normal

Common NOS3 allele — normal blood pressure baseline

You carry two copies of the G allele (the common form at rs891512). Your NOS3 gene splices normally at intron 25, supporting standard eNOS protein production and nitric oxide output. This genotype was associated with the lowest resting blood pressure among the three genotype groups in the MRC Ely Study, with the protective effect strongest in physically active individuals.

About 65% of people globally carry this genotype. It is much less common in Europeans (~62%) where the A allele reaches a frequency of about 21%, and very common in East Asian and African populations (~97% and ~96% GG respectively).

AG One Risk Allele Intermediate

One A allele — modestly elevated blood pressure, exercise amplifies the gap

As a heterozygote, roughly half of your NOS3 transcripts carry the A allele at the intron 25 splice region. Bioinformatic analysis predicts this alters SF2/ASF splicing factor binding, potentially yielding a subset of truncated eNOS protein that forms heterodimers with full-length enzyme and reduces total NO output. The net effect is intermediate eNOS function.

The gene-exercise interaction documented in the MRC Ely Study has direct practical implications: GG homozygotes who are habitually active show BP reductions of ~4.9/3.8 mmHg (diastolic/systolic) relative to inactive GG carriers. For A-allele carriers, this physical activity benefit is partially offset by the splicing impairment, emphasizing that regular vigorous exercise is especially important for maintaining cardiovascular health in this genotype group.

In a Tunisian cohort, being an A-allele carrier was associated with approximately doubled odds of coronary artery disease compared to GG homozygotes, with consistent trends in other cardiovascular disease studies.

AA Two Risk Alleles Reduced

Two A alleles — elevated cardiovascular risk, strongly exercise-responsive

With both NOS3 alleles carrying the A variant at IVS25+15, the predicted disruption to SF2/ASF splicing factor binding affects all eNOS transcripts. The likely result is a larger fraction of aberrantly-spliced transcripts encoding truncated eNOS proteins, which form inactive heterodimers with any remaining full-length enzyme and further reduce NO output.

The clinical consequence is a baseline shift toward elevated blood pressure and impaired endothelial function. In the Tunisian case-control study, the AA genotype was present in 11.4% of CAD cases versus only 2.5% of controls — a 4.6-fold enrichment — corresponding to an A-allele OR for CAD of 1.99 (95% CI 1.40–2.82). The exercise-intensified BP lowering in GG carriers from the Ely Study implies that AA homozygotes show the smallest exercise-mediated BP benefit from the NOS3 genetic architecture, making the dietary nitrate pathway a critical compensatory mechanism.

Post-exercise hypotension data add nuance: after vigorous-intensity cycling in African Americans, rs891512 minor alleles were associated with a larger post-exercise BP drop (30.4 mmHg systolic, P < 0.001), suggesting the exercise response remains substantial even in minor allele carriers. This finding is encouraging but based on a small African American sample and requires replication.